Tags

Type your tag names separated by a space and hit enter

Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer.
Oncology. 2017; 93(2):122-126.O

Abstract

OBJECTIVE

The aim of this study was to evaluate disease-specific survival and cost related to radioactive iodine therapy (RAI) utilization in patients with early-stage papillary thyroid carcinoma (PTC).

METHODS

This was a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, 2004-2012.

RESULTS

A total of 38,374 patients with PTC were identified. Of those, 56.3% had adjuvant RAI. RAI administration was not associated with a survival advantage in patients with PTC stage I (hazard ratio [HR] 1.26, 95% confidence interval [CI] 0.11, 14.54; p = 0.85) or stage II (HR 0.50, 95% CI 0.05, 4.88; p = 0.55). Patients with PTC stage III who underwent adjuvant RAI had an improved survival (HR 0.30, 95% CI 0.10, 0.91; p = 0.033). In 2012, RAI was used in 45.5% of patients with stage I and in 71.4% of patients with stage II. The total expenditure on adjuvant RAI for PTC stage I throughout the study period was estimated to be USD 82.3 million with an annual average of USD 9.1 (±2.0) million/year. If the decline rate in the utilization of RAI continued, the model projected that the annual expenditure would decrease by USD 0.14 million/year.

CONCLUSION

There is a high prevalence of adjuvant RAI utilization for early-stage PTC that is causing financial burden on the health system with no evidence of survival benefit.

Authors+Show Affiliations

Department of Otolaryngology - Head and Neck Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28609768

Citation

Al-Qurayshi, Zaid, et al. "Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer." Oncology, vol. 93, no. 2, 2017, pp. 122-126.
Al-Qurayshi Z, Bu Ali D, Srivastav S, et al. Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. Oncology. 2017;93(2):122-126.
Al-Qurayshi, Z., Bu Ali, D., Srivastav, S., & Kandil, E. (2017). Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. Oncology, 93(2), 122-126. https://doi.org/10.1159/000466700
Al-Qurayshi Z, et al. Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. Oncology. 2017;93(2):122-126. PubMed PMID: 28609768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. AU - Al-Qurayshi,Zaid, AU - Bu Ali,Daniah, AU - Srivastav,Sudesh, AU - Kandil,Emad, Y1 - 2017/06/14/ PY - 2017/01/16/received PY - 2017/02/14/accepted PY - 2017/6/14/pubmed PY - 2017/10/24/medline PY - 2017/6/14/entrez KW - National cost KW - Radioactive iodine KW - Survival KW - Thyroid cancer KW - Utilization rate SP - 122 EP - 126 JF - Oncology JO - Oncology VL - 93 IS - 2 N2 - OBJECTIVE: The aim of this study was to evaluate disease-specific survival and cost related to radioactive iodine therapy (RAI) utilization in patients with early-stage papillary thyroid carcinoma (PTC). METHODS: This was a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database, 2004-2012. RESULTS: A total of 38,374 patients with PTC were identified. Of those, 56.3% had adjuvant RAI. RAI administration was not associated with a survival advantage in patients with PTC stage I (hazard ratio [HR] 1.26, 95% confidence interval [CI] 0.11, 14.54; p = 0.85) or stage II (HR 0.50, 95% CI 0.05, 4.88; p = 0.55). Patients with PTC stage III who underwent adjuvant RAI had an improved survival (HR 0.30, 95% CI 0.10, 0.91; p = 0.033). In 2012, RAI was used in 45.5% of patients with stage I and in 71.4% of patients with stage II. The total expenditure on adjuvant RAI for PTC stage I throughout the study period was estimated to be USD 82.3 million with an annual average of USD 9.1 (±2.0) million/year. If the decline rate in the utilization of RAI continued, the model projected that the annual expenditure would decrease by USD 0.14 million/year. CONCLUSION: There is a high prevalence of adjuvant RAI utilization for early-stage PTC that is causing financial burden on the health system with no evidence of survival benefit. SN - 1423-0232 UR - https://www.unboundmedicine.com/medline/citation/28609768/Financial_Implication_of_Radioactive_Iodine_Therapy_for_Early_Stage_Papillary_Thyroid_Cancer_ L2 - https://www.karger.com?DOI=10.1159/000466700 DB - PRIME DP - Unbound Medicine ER -